Wolfgang Wick

This inventor holds 9 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 8 EPO patents. Top assignees: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universitat Heidelberg, Dc Europa Limited. Active years: 2013-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wolfgang Wick. Retrieved from https://idiyas.com/inventor/wolfgang-wick-hy5gggv3

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 9 (Patent Applications = 5)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 8 (Patent Applications = 14)

Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 13(Granted Patents)

Company Filing History:

5 out of 159

Deutsches Krebsforschungszentrum

patents

2 out of 64

Ruprecht-Karls-Universitat Heidelberg

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts and Ruprecht-Karls-Univeristat Heidelberg

patent

5. 1 out of 1

Deutschland Krebsforschungszentrum

patent

6. 1 out of 2

Ruprecht-Karis-Universität Heidelberg

patents

7. 1 out of 1

Ruprecht-Karls-Univeristaet Heidelberg

patent

8. 1 out of 34

Universitat Heidelberg

patents

where one patent can have more than one assignee

Years Active: 2013-2024

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12029789 - Agent for use in the treatment of glioma (2024-07-09),

2. 11964015 - Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor (2024-04-23),

3. 11767352 - Histone anti-cancer vaccines (2023-09-26),

4. 11246927 - Agents for use in the treatment of glioma (2022-02-15),

5. 11027013 - Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor (2021-06-08),

6. 10813959 - Cancer therapy with a parvovirus combined with bevacizumab (2020-10-27),

7. 10161940 - Means and methods for treating or diagnosing IDH1 R132H mutant-positive cancers (2018-12-25),

8. 9593062 - Means and methods for treating and/or preventing natural AHR ligand-dependent cancer (2017-03-14),

9. 8367347 - Methods for the diagnosis and the prognosis of a brain tumor (2013-02-05),

Title: The Innovative Contributions of Wolfgang Wick in Glioma Treatment

Introduction

Wolfgang Wick is a prominent inventor based in Heidelberg, Germany, known for his significant contributions to cancer research and treatment. With a total of nine patents, his work particularly focuses on developing novel therapeutic agents for glioma, a type of brain tumor.

Latest Patents

Wick's latest patents include groundbreaking inventions aimed at advancing glioma treatment. One notable patent is for an agent designed for the treatment of glioma, including various grades of astrocytoma and glioblastoma. This invention offers new hope to patients suffering from these challenging conditions. Another recent patent addresses cancer therapy using a combination of an oncolytic virus and a checkpoint inhibitor, highlighting a synergistic approach to enhance treatment efficacy.

Career Highlights

Throughout his career, Wolfgang Wick has been associated with prestigious institutions that have propelled his research forward. He has worked at the German Cancer Research Center (Deutsches Krebsforschungszentrum) and the Heidelberg University (Ruprecht-Karls-Universität Heidelberg), where he has significantly contributed to the field of oncology.

Collaborations

Wick has collaborated with renowned colleagues such as Michael Platten and Jean Rommelaere, further enriching his research endeavors and expanding the impact of his inventions. These partnerships exemplify the collaborative effort required in pioneering advancements in medical science.

Conclusion

Wolfgang Wick stands out as an influential inventor in the realm of cancer treatment. Through his innovative patents and collaborative work, he is making strides toward improving therapeutic options for glioma patients. His contributions reflect a commitment to advancing medical knowledge and patient care in the field of oncology.

Profile summary based on public USPTO records.